Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that is characterized by the development of multiple vascular tumors and is caused by inactivation of the von Hippel-Lindau protein (pVHL). Here we show that pVHL, through its beta-domain, binds directly to hypoxia-inducible factor (HIF), thereby targeting HIF for ubiquitination in an alpha-domain-dependent manner. This is the first function to be ascribed to the pVHL beta-domain. Furthermore, we provide the first direct evidence that pVHL has a function analogous to that of an F-box protein, namely, to recruit substrates to a ubiquitination machine. These results strengthen the link between overaccumulation of HIF and development of VHL disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the presence of oxygen (typically > 5% O2), the HIF-α subunit is hydroxylated by PHDs in an iron and oxygen dependent manner, which leads to HIF-α polyubiquitination by pVHL, targeting HIF-α for proteasomal degradation (Figure 2) [8].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [8]
In the citing paper
“As described in the AdPROM section, VHL acts as the substrate receptor for the Cul2-Rbx1 E3 ligase complex, recruiting HIF1α for its ubiquitination and degradation [88].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [88]
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 1×
“Whether hypoxia and desferroxamine utilize the same molecular mechanism(s) to stabilize HIF in vivo remains to be determine”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
Self-citationStabilization of wild-type p53 by hypoxia-inducible factor 1α
An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., & Neckers, L. M. (1998) · Nature · doi:10.1038/32925 · Cited by 827
Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway
Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., & Poellinger, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6519 · Cited by 754
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Self-citationBinding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citationKamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Conaway, R. C., & Conaway, J. W. (1998) · Genes & Development · doi:10.1101/gad.12.24.3872 · Cited by 595 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citation
Cited by
Items 501–600 of 1,005
Epigallocatechin gallate inhibits HIF-1α degradation in prostate cancer cells
Thomas, R., & Kim, M. H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.114 · Cited by 82
PIASy stimulates HIF1α SUMOylation and negatively regulates HIF1α activity in response to hypoxia
Kang, X., Li, J., Zou, Y., Yi, J., Zhang, H., Cao, M., Yeh, E. T. H., & Cheng, J. (2010) · Oncogene · doi:10.1038/onc.2010.297 · Cited by 82
“Interestingly, region 331–698 amino acid is the ODD domain of HIF1a containing SUMO conjugation sites (Ohh et al., 2000; Ivan et al., 2001; Jaakkola et al., 2001).”
BackgroundHypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures
Jensen, R. L. (2006) · Neurosurgical Focus · doi:10.3171/foc.2006.20.4.16 · Cited by 76
The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma
Sufan, R. I., Jewett, M. A. S., & Ohh, M. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00424.2003 · Cited by 80
Self-citationROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells
Chetram, M. A., Bethea, D. A., Odero-Marah, V., Don-Salu-Hewage, A. S., Jones, K. J., & Hinton, C. V. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1549-7 · Cited by 77
Anchoring Proteins as Regulators of Signaling Pathways
Perino, A., Ghigo, A., Scott, J. D., & Hirsch, E. (2012) · Circulation Research · doi:10.1161/circresaha.111.262899 · Cited by 78
Imidazole Ring-Opened DNA Purines and Their Biological Significance
Tudek, B. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.012 · Cited by 85
VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives
Wang, C., Zhang, Y., Wang, J., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113906 · Cited by 76
Beischlag, T. V., Taylor, R. T., Rose, D. W., Yoon, D., Chen, Y., Lee, W.-H., Rosenfeld, M. G., & Hankinson, O. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410456200 · Cited by 74
Koeman, J. M., Russell, R. C., Tan, M., Petillo, D., Westphal, M., Koelzer, K., Metcalf, J. L., Zhang, Z., Matsuda, D., Dykema, K. J., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000176 · Cited by 74
“In Vitro Ubiquitylation Assay An in vitro ubiquitylation assay was performed as described previously [3].”
MethodSelf-citationvon Hippel–Lindau tumor suppressor: not only HIF's executioner
Czyzyk-Krzeska, M., & Meller, J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.02.004 · Cited by 77
Park, S., Bae, I., & Lee, Y. J. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21588 · Cited by 81
“Subsequently, pVHL binds to the hydroxylated HIF-1a and marks it for proteasomal degradation by ubiquitination [Ohh et al., 2000].”
BackgroundInfluentialKnauth, K., Bex, C., Jemth, P., & Buchberger, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209062 · Cited by 84
“…ubiquitylation of HIF-1a, conflicting data exist in the literature regarding the downregulation of HIF-1a in vivo by type 2A versus type 2B mutant pVHL. Ohh et al. (1999, 2000) did not observe restoration of HIF-1/2a downregulation in pVHL-defective RCC cell lines upon reintroduction of pVHLY98H.”
BackgroundMethodInfluentialBuilding better vasculature: Figure 1.
Bruick, R. K., & McKnight, S. L. (2001) · Genes & Development · doi:10.1101/gad.931601 · Cited by 79
“VEGF administration has been shown to promote the recruitment of circulating endothelial progenitor cells into sites of vascular assembly (Asahara et al. 1999) and to activate proteases required for invasion (Pepper et al. 1991).”
BackgroundSuperoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors
Görlach, A., & Kietzmann, T. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35022-2 · Cited by 73
“This action allows binding of the von Hippel-Lindau tumor suppressor protein (pVHL) (Maxwell et al., 1999; Min et al., 2002; Ohh et al., 2000; Tanimoto et al., 2000), which initiates ubiquitinylation and proteasomal degradation (Ivan et al.”
BackgroundKoh, M. Y., Spivak-Kroizman, T. R., & Powis, G. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-78281-0_3 · Cited by 86
Liu, M. Y., Poellinger, L., & Walker, C. L. (2003) · PubMed · Cited by 83
TIP120A Associates with Cullins and Modulates Ubiquitin Ligase Activity
Min, K.-W., Hwang, J.-W., Lee, J.-S., Park, Y., Tamura, T.-A., & Yoon, J.-B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213070200 · Cited by 71
The von Hippel-Lindau Tumor Suppressor Protein: Roles in Cancer and Oxygen Sensing
Kaelin, W. G. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.001 · Cited by 80
Self-citationUbiquitin Pathway in VHL Cancer Syndrome
Ohh, M. (2006) · Neoplasia · doi:10.1593/neo.06442 · Cited by 76
Self-citationColeman, K. G., & Crews, C. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050430 · Cited by 66
“VHL mediates the polyubiquitination and degradation of HIF-1α, which is a transcription factor that plays a central role in a cell’s response to hypoxia (Wang et al. 1995, Ohh et al. 2000).”
BackgroundHIF-1α and iNOS levels in crucian carp gills during hypoxia-induced transformation
Sollid, J., Rissanen, E., Tranberg, H. K., Thorstensen, T., Vuori, K. A. M., Nikinmaa, M., & Nilsson, G. (2005) · Journal of Comparative Physiology B · doi:10.1007/s00360-005-0059-2 · Cited by 78
“2), are the minimum motifs for association with the von Hippel–Lindau tumor suppressor E3 ubiquitin ligase (VHLE3), which targets HIF-1a for degradation (Masson et al. 2001; Ohh et al. 2000; Tanimoto et al. 2000).”
BackgroundIntracellular energy production and distribution in hypoxia
Flood, D., Lee, E. S., & Taylor, C. T. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105103 · Cited by 73
VHL mutation analysis in patients with isolated central nervous system haemangioblastoma
Woodward, E. R., Wall, K., Forsyth, J., MacDonald, F., & Maher, E. R. (2007) · Brain · doi:10.1093/brain/awl362 · Cited by 73
“The VHL gene product has multiple functions, but the best characterized is as a key component of an E3 ubiquitin ligase complex that targets the -subunits of the HIF (hypoxia-inducible factor) transcription factors for ubiquitylation and proteasomal degradation (Maxwell et al., 1999; Cockman et al., 2000; Ohh et al.,…”
BackgroundMorris, M. R., Maina, E., Morgan, N. V., Gentle, D., Astuti, D., Moch, H., Kishida, T., Yao, M., Schraml, P., Richards, F. M., et al. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.011767 · Cited by 70
Kwon, S. J., & Lee, Y. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2530 · Cited by 67
Simpson, L. M., Macartney, T. J., Nardin, A., Fulcher, L. J., Röth, S., Testa, A., Maniaci, C., Ciulli, A., Ganley, I. G., & Sapkota, G. P. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.06.013 · Cited by 66
“(legend on next page) ll OPEN ACCESSArticle Cell Chemical Biology 27, 1164–1180, September 17, 2020 1165 ll OPEN ACCESS Article ubiquitylation and subsequent degradation by the proteasome (Ohh et al., 2000; Ivan et al., 2001; Jaakkola et al., 2001).”
BackgroundMolecular Genetics of Familial Renal Cell Carcinoma Syndromes
Cohen, D., & Zhou, M. (2005) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2005.01.003 · Cited by 75
“HIF a subunits are ubiquitinated and degraded and undetectable in normoxic cells upon binding to pVHL’s b domain [30].”
BackgroundBeń‐Skowronek, I., & Kozaczuk, S. (2015) · Hormone Research in Paediatrics · doi:10.1159/000431323 · Cited by 71
Use of PROTACS as molecular probes of angiogenesis
Bargagna‐Mohan, P., Baek, S., Lee, H., Kim, K., & Mohan, R. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.04.008 · Cited by 70
Mechanism of Cancer Cell Adaptation to Metabolic Stress
Liu, R. R., Li, Z., Bai, S., Zhang, H., Tang, M., Lei, Y., Chen, L., Liang, S., Zhao, Y., Wei, Y., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800195-mcp200 · Cited by 72
“to HIF by the von Hippel-Lindau (VHL) protein [5-6].”
MethodLi, X., Cui, X., Chen, Y., Wu, T., Xu, H., Yin, H., & Wu, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00121 · Cited by 70
“HIF-1α protein is degraded through hydroxylation by PHD, which promotes the interaction between HIF-1α and the pVHL ubiquitin E3 ligase complex (Maxwell et al., 1999; Srinivas et al., 1999; Ohh et al., 2000).”
BackgroundChen, L., Uchida, K., Endler, A., & Shibasaki, F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700423200 · Cited by 66
Leu‐574 of human HIF‐1α is a molecular determinant of prolyl hydroxylation
Kageyama, Y., Koshiji, M., To, K. K. W., Tian, Y., Ratcliffe, P. J., & Huang, L. E. (2004) · The FASEB Journal · doi:10.1096/fj.03-1233fje · Cited by 68
ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma
Green, Y. S., Ferreira dos Santos, M. C., Fuja, D. G., Reichert, E. C., Campos, A. R., Cowman, S. J., Acuña Pilarte, K., Kohan, J., Tripp, S. R., Leibold, E. A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02460-1 · Cited by 69
Proteomic approaches advancing targeted protein degradation
Sathe, G. J., & Sapkota, G. P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.08.007 · Cited by 73
Advanced Renal Cell Carcinoma: Current and Emerging Management Strategies
Escudier, B. J. (2007) · Drugs · doi:10.2165/00003495-200767090-00002 · Cited by 69
Ruas, J. L., Berchner-Pfannschmidt, U., Malik, S., Gradin, K., Fandrey, J., Roeder, R. G., Pereira, T., & Poellinger, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.021824 · Cited by 65
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy
Pfaffenroth, E. C., & Linehan, W. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.779 · Cited by 80
“Inactivating mutations of both copies of VHL produce a similar effect as hypoxia, by inhibiting binding of the VHL complex and preventing HIF degradation, thus allowing HIF to overaccumulate [32,33] .”
BackgroundHaque, M., Wang, V. E. H., Davis, D. A., Zheng, Z., & Yarchoan, R. (2006) · Journal of Virology · doi:10.1128/jvi.00553-06 · Cited by 75
“and degradation via the proteasome (10, 36, 46, 51).”
BackgroundZhang, C., Lu, L., Li, Y., Wang, X., Zhou, J., Liu, Y., Fu, P., Gallicchio, M. A., Bach, L. A., & Duan, C. (2012) · International Journal of Cancer · doi:10.1002/ijc.26201 · Cited by 67
“HREs are present in many angiogenic genes including vascular endothelial growth factor (VEGF), a major angiogenic gene, and its receptor, Flk1.”
BackgroundHypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
GAO, C., Peng, F., & PENG, L. K. (2014) · Neoplasma · doi:10.4149/neo_2014_083 · Cited by 67
“Sorafinib is an orally available, novel bi-aryl urea compound that represses tumor growth and metastases by targeting the receptor tyrosine kinases VEGFR and PDGFR to inhibit angiogenesis and proliferation[2].”
BackgroundInfluentialShi, M., Dai, W., Jia, R.-R., Zhang, Q., Wei, J., Wang, Y., Xiang, S., Liu, B., & Xu, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.011 · Cited by 73
Cellular oxygen sensing in health and disease
Mole, D. R., & Ratcliffe, P. J. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0632-x · Cited by 79
Hypoxia and Hypoxia Inducible Factors (HIF) as Important Regulators of Tumor Physiology
Acker, T., & Plate, K. H. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_14 · Cited by 75
Hypoxia and High Altitude: The molecular response
Höpfl, G., Ogunshola, O. O., & Gassmann, M. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8997-0_7 · Cited by 73
Proteostasis Modulators Prolong Missense VHL Protein Activity and Halt Tumor Progression
Yang, C., Huntoon, K. M., Ksendzovsky, A., Zhuang, Z., & Lonser, R. R. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.007 · Cited by 66
“, 2001), which is responsible for binding, targeting, and degrading hypoxia-inducible factor (HIF)-1a/HIF-2a via the ubiquitin proteasome pathway (Cockman et al., 2000; Maxwell et al., 1999; Ohh et al., 2000).”
BackgroundInfluentialEffect of chemical stabilizers of hypoxia-inducible factors on early lung development
Groenman, F. A., Rutter, M., Wang, J., Caniggia, I., Tibboel, D., & Post, M. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00486.2006 · Cited by 77
“Under normoxic conditions, proline residues 402 and 564 of the -subunit are rapidly hydroxylated by prolyl hydroxylase domain enzymes (PHD1-3) allowing recognition of the -subunit by the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex and subsequent proteosomal degradation (36, 40).”
Invited Review: Effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest
Douglas, R. M., & Haddad, G. G. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01029.2002 · Cited by 72
Zhou, M. I., Wang, H., Foy, R. L., Ross, J. J., & Cohen, H. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0884 · Cited by 62
In vitro and In vivo Models Analyzing von Hippel-Lindau Disease-Specific Mutations
Rathmell, W. K., Hickey, M. M., Bezman, N. A., Chmielecki, C. A., Carraway, N. C., & Simon, M. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1430 · Cited by 64
Detecting and responding to hypoxia
Zhu, H., Jackson, T., & Bunn, H. F. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.suppl_1.3 · Cited by 66
Renal Cell Carcinoma: Molecular Aspects
Kumar, A., Kumari, N., Gupta, V., & Prasad, R. (2017) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0713-y · Cited by 67
“The beta domain mediates the interaction of pVHL with the substrates of E3 ubiquitin ligase [22].”
Oxygen sensing, HIF-1α stabilization and potential therapeutic strategies
Höfer, T., Wenger, R. H., & Gassmann, M. (2002) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-001-0759-8 · Cited by 76
mAKAP Compartmentalizes Oxygen-Dependent Control of HIF-1α
Wong, W., Goehring, A. S., Kapiloff, M. S., Langeberg, L. K., & Scott, J. D. (2008) · Science Signaling · doi:10.1126/scisignal.2000026 · Cited by 65
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Roxadustat Markedly Reduces Myocardial Ischemia Reperfusion Injury in Mice
Deguchi, H., Ikeda, M., Ide, T., Tadokoro, T., Ikeda, S., Okabe, K., Ishikita, A., Saku, K., Matsushima, S., & Tsutsui, H. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-1039 · Cited by 69
Masuda, K., Ono, M., Okamoto, M., Morikawa, W., Otsubo, M., Migita, T., Tsuneyoshi, M., Okuda, H., Shuin, T., Naito, S., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11152 · Cited by 63
Harnessing the Response to Tissue Hypoxia HIF-1α and Therapeutic Angiogenesis
Vincent, K. A., Féron, O., & Kelly, R. A. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00186-x · Cited by 70
Role of hypoxia in tumor angiogenesis?molecular and cellular angiogenic crosstalk
Acker, T., & Plate, K. H. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0763-8 · Cited by 71
Datta, K., Li, J., Bhattacharya, R., Gasparian, L., Wang, E., & Mukhopadhyay, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2706 · Cited by 68
“It has also been demonstrated that pVHL contributes to the ubiquitination and degradation of hypoxia-inducible factor (HIF)-1 under normoxic conditions (9, 13).”
BackgroundPioli, P. A., & Rigby, W. F. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105391200 · Cited by 63
Cellular and Molecular Mechanisms Underlying Oxygen-Dependent Radiosensitivity
Liu, C., Lin, Q., & Yun, Z. (2015) · Radiation Research · doi:10.1667/rr13959.1 · Cited by 68
“The hydroxylated HIF-a is ubiquitinated via interaction with the von Hippel-Lindau (VHL) protein in the E3 ubiquitin ligase complex and eventually degraded by proteasomes (36, 37).”
BackgroundMicroRNA‐31 targets FIH‐1 to positively regulate corneal epithelial glycogen metabolism
Peng, H., Hamanaka, R. B., Katsnelson, J., Hao, L., Yang, W., Chandel, N. S., & Lavker, R. M. (2012) · The FASEB Journal · doi:10.1096/fj.11-198515 · Cited by 63
“During normoxia, HIF-1 is polyubiquitinated and targeted for degradation by an E3 ubiquitin ligase complex that contains the von Hippel-Lindau tumor suppressor protein (pVHL), elongin B, elongin C, Cul2, and Rbx (13, 14).”
BackgroundBlees, J. S., Bokesch, H. R., Rübsamen, D., Schulz, K., Milke, L., Bajer, M. M., Gustafson, K. R., Henrich, C. J., McMahon, J. B., Colburn, N. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046567 · Cited by 62
“Therefore, we analyzed the effect of erioflorin on the stability of HIF-1a protein, which is targeted for proteasomal degradation by the E3-ligase von HippelLindau protein (pVHL) [41].”
BackgroundThe Hypoxia–Adenosine Link during Intestinal Inflammation
Bowser, J. L., Phan, L. H., & Eltzschig, H. K. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701414 · Cited by 65
Seliger, B., Fedorushchenko, A., Brenner, W., Ackermann, A., Atkins, D., Hanash, S., & Lichtenfels, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0824 · Cited by 63
Tajima, N., Schönherr, K., Niedling, S., Kaatz, M., Kanno, H., Schönherr, R., & Heinemann, S. H. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.096818 · Cited by 61
“2001) and thereby allow binding of the von Hippel-Lindau protein (pVHL) to HIF-1α (Maxwell et al. 1999; Ohh et al. 2000).”
BackgroundCybulski, C., Krzystolik, K., Murgia, A., Górski, B., Dębniak, T., Jakubowska, A., Martella, M., Kurzawski, G., Prost, M., Kojder, I., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.7.e38 · Cited by 63
Genetic Analysis of Hypoxia Signaling and Response in C. elegans
SHEN, C., & POWELL‐COFFMAN, J. A. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03222.x · Cited by 60
Kamura, T., Brower, C. S., Conaway, R., & Conaway, J. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203344200 · Cited by 68
Saturation genome editing maps the functional spectrum of pathogenic VHL alleles
Buckley, M., Terwagne, C., Ganner, A., Cubitt, L., Brewer, R., Kim, D.-K., Kajba, C. M., Forrester, N., Dace, P., De Jonghe, J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01800-z · Cited by 62
“Loss of VHL function due to mutation can lead to constitutive HIF activity and tumor development 17 .”
A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer
Satija, Y. K., Bhardwaj, A., & Das, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28129 · Cited by 71
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies
Chowdhury, S., Larkin, J., & Gore, M. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.028 · Cited by 65
Perinatal oxygen in the developing lung
Vogel, E. R., Britt, R. D., Trinidad, M. C., Faksh, A., Martin, R. J., MacFarlane, P. M., Pabelick, C. M., & Prakash, Y. S. (2014) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2014-0387 · Cited by 67
“Oxygen is rapidly utilized as a substrate by prolyl hydroxylases (PHD 1–3) to hydroxylate proline residues on the HIF -subunit (Maxwell et al. 1999; Ohh et al. 2000).”
BackgroundPositive regulation of HIF-1A expression by EBV oncoprotein LMP1 in nasopharyngeal carcinoma cells
Sung, W., Chu, Y.-C., Chen, P., Liao, M., & Lee, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.021 · Cited by 62
Polycythemia vera and other primary polycythemias
Prchal, J. T. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000154029.05396.d2 · Cited by 65
Saturation Genome Editing Resolves the Functional Spectrum of Pathogenic VHL Alleles
Buckley, M., Kajba, C. M., Forrester, N., Terwagne, C., Sawyer, C., Shepherd, S. T. C., Jonghe, J. D., Dace, P., Turajlic, S., & Findlay, G. M. (2023) · doi:10.1101/2023.06.10.542698 · Cited by 62
Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma
Santoni, M., Pantano, F., Amantini, C., Nabissi, M., Conti, A., Burattini, L., Zoccoli, A., Berardi, R., Santoni, G., Tonini, G., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.007 · Cited by 66
NRF2 in human neoplasm: Cancer biology and potential therapeutic target
Liu, Y., Lang, F., & Yang, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107664 · Cited by 61
Ikeda, H., & Kakeya, H. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00451-0 · Cited by 65
Regulation of vitamin metabolism by p53 and p63 in development and cancer
Zhou, H., & van Bokhoven, H. (2010) · Cell Cycle · doi:10.4161/cc.9.14.12591 · Cited by 61
Chen, C., Zhou, H., Wei, F., Jiang, L., Liu, X., Liu, Z., & Ma, Q. (2010) · Journal of Orthopaedic Research® · doi:10.1002/jor.21193 · Cited by 64
“Based on the surgical staging system of the Musculoskeletal Tumor Society (MSTS),28 lesions were correspondingly identified as: stage IA (12), stage IB (10), stage IIA (6), and stage IIB (6).”
MethodNEDD8 acts as a ‘molecular switch’ defining the functional selectivity of VHL
Russell, R. C., & Ohh, M. (2008) · EMBO Reports · doi:10.1038/embor.2008.19 · Cited by 69
“Human embryonic kidney (HEK)293A cells were transfected with plasmids encoding T7-NEDD8 in combination with plasmids encoding HAVHL(WT), non-neddylatable HA-VHL(RRR) and HA-VHL(C162F), a well-established a-domain mutant unable to bind to Elongin C (Ohh et al, 2000, 1999).”
BackgroundMethodSelf-citationRegulation of the endothelial cell cycle by the ubiquitin-proteasome system
Fasanaro, P., Capogrossi, M. C., & Martelli, F. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp244 · Cited by 65
Shao, Z., Zhang, Y., & Powell‐Coffman, J. A. (2009) · Genetics · doi:10.1534/genetics.109.107284 · Cited by 70
Tumor Suppression by the von Hippel-Lindau Protein Requires Phosphorylation of the Acidic Domain
Lolkema, M. P., Gervais, M. L., Snijckers, C. M. J. T., Hill, R. P., Giles, R. H., Voest, E. E., & Ohh, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503220200 · Cited by 66
Self-citationKrek, W. (2000) · Nature Cell Biology · doi:10.1038/35017129 · Cited by 61
Lactylation modification of HIF-1α enhances its stability by blocking VHL recognition
Li, C., Fu, C., Zhou, W., Li, H., Liu, Z., Wu, G., He, T., Shen, M., & Liu, H. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02366-x · Cited by 60
“VHL binds to a region of HIF-1α known as the ODD (aa 401–603) [24].”
Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Said, H. M., Supuran, C. T., Hageman, C., Staab, A., Polat, B., Katzer, A., Scozzafava, A., Anacker, J., Flentje, M. P., & Vordermark, D. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793429788 · Cited by 68
“In normoxia, the von Hippel- Lindau tumour suppressor, which is the E3 ubiquitin ligase complex recognition component, targets HIF-1 [16, 17] leading to its ubiquitylation and consequent proteasomal degradation [16-21].”
BackgroundProlyl Hydroxylase PHD3 Activates Oxygen-dependent Protein Aggregation
Rantanen, K., Pursiheimo, J., Högel, H., Himanen, V., Metzen, E., & Jaakkola, P. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-11-1124 · Cited by 69
“The hydroxylated HIF-1 is recognized by the von Hippel-Lindau tumor suppressor protein (pVHL) that subsequently leads to ubiquitination and proteosomal destruction of HIF-1 (Kallio et al., 1999; Maxwell et al., 1999; Cockman et al., 2000; Ohh et al., 2000; Tanimoto et al., 2000).”
BackgroundPires, B. R. B., de Amorim, Í. S. S., Souza, L. D. E., Rodrigues, J. A., & Mencalha, A. L. (2016) · Anticancer Research · doi:10.21873/anticanres.11151 · Cited by 65
Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury
Li, X., Berg, N. K., Mills, T., Zhang, K., Eltzschig, H. K., & Yuan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604944 · Cited by 64
“The normoxic stabilization of HIF-1a is dependent on the inhibition of proteasome function and decreasing the expression of factor inhibiting HIF-1 (FIH-1) (86).”
BackgroundBerchner‐Pfannschmidt, U., Petrat, F., Doege, K., Trinidad, B., Freitag, P., Metzen, E., de GROOT, H., & Fandrey, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313995200 · Cited by 67
The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation
Strocchi, S., Reggiani, F., Gobbi, G., Ciarrocchi, A., & Sancisi, V. (2022) · Oncogene · doi:10.1038/s41388-022-02378-8 · Cited by 61
Hypoxia-regulated gene network in drug resistance and cancer progression
Lin, S.-C., Liao, W.-L., Lee, J., & Tsai, S. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214532755 · Cited by 61
Signals and pathways controlling regulatory T cells
Huynh, A., Zhang, R., & Turka, L. A. (2014) · Immunological Reviews · doi:10.1111/imr.12148 · Cited by 66
“Under normoxic conditions, HIF-1a is first hydroxylated on its proline residues, then polyubiquitinated by von Hippel-Lindau protein (pVHL) and rapidly degraded by the proteasome; hypoxic conditions prevent the initial hydroxylation of HIF-1a therefore preventing protein degradation (163, 164).”
BackgroundEnvironmental and Metabolic Sensors That Control T Cell Biology
Ramsay, G., & Cantrell, D. A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00099 · Cited by 62
“This rapid degradation occurs because proline residues of HIF-1α become hydroxylated by prolyl hydroxylases after which HIF-1α is ubiquitinated by the vonHippel–Lindau (Vhl) E3 ligase complex (32, 33) with the resultant targeting of HIF-1α for degradation.”
BackgroundLoss of Fibroblast HIF-1α Accelerates Tumorigenesis
Kim, J.-W., Evans, C., Weidemann, A., Takeda, N., Lee, Y. S., Stockmann, C., Branco-Price, C., Brandberg, F., Leone, G., Ostrowski, M. C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0534 · Cited by 57
“through a complex containing the pVHL tumor suppressor (17).”
Metadata
- Authors
- Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Pennsylvania State University (US)
- Corresponding author
- Kaelin, William G.
- Venue
- Nature Cell Biology
- Published
- 2000-06-09
- Volume
- 2
- Issue
- 7
- Pages
- 423-427
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2147718842
- Cited by
- 1,577
- References
- 21
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 46 · 2023: 36 · 2022: 49 · 2021: 56 · 2020: 59 · 2019: 45 · 2018: 40 · 2017: 50 · 2016: 52 · 2015: 45 · 2014: 62 · 2013: 66 · 2012: 70
- FWCI
- 33.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- von Hippel-Lindau protein, hypoxia-inducible factor, ubiquitination, F-box protein, protein-protein interaction, alpha-domain, von Hippel-Lindau disease, tumor suppressor, vascular tumors, E3 ubiquitin ligase
- MeSH terms
- Elongin, Cell Extracts, Deferoxamine, DNA-Binding Proteins, HeLa Cells, Humans, Ligases, Mutation, Nuclear Proteins, Oxygen, Protein Binding, Protein Processing, Post-Translational, Proteins, Transcription Factors, Transfection, Tumor Cells, Cultured, Ubiquitins, Protein Structure, Tertiary, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.